CYP2C19 and major depressive disorder: Likewise, Morinobu et al. [28] observed no significant differences in onset age, HAMD scale scores before treatment, or imipramine dosage between Japanese MDD patients with and without the CYP2C19′s *2 (m1) and *3 (m2) polymorphisms.